Citadel Advisors’s Revelation Biosciences Warrant REVBW Stock Holding History

Citadel Advisors’s Portfolio REVBW Stock Details REVBW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$285	Buy	32,400 +302	+0.9%	+$3	﹤0.01%	12856
2025 Q4	$257	Buy	32,098 +300	+0.9%	+$3	﹤0.01%	12505
2025 Q3	$321	Sell	31,798 -4,250	-12%	-$61	﹤0.01%	12616
2025 Q2	$433	Sell	36,048 -520	-1%	-$6	﹤0.01%	12290
2025 Q1	$366	Sell	36,568 -1,667	-4%	-$26	﹤0.01%	14276
2024 Q4	$268	Buy	38,235 +8,835	+30%	+$103	﹤0.01%	14357
2024 Q3	$423	Sell	29,400 -16,453	-36%	-$230	﹤0.01%	14020
2024 Q2	$917	Sell	45,853 -674	-1%	-$11	﹤0.01%	13890
2024 Q1	$1.23K	Buy	46,527 +32,266	+226%	+$445	﹤0.01%	14158
2023 Q4	$151	Sell	14,261 -2,220	-13%	-$28	﹤0.01%	14113
2023 Q3	$279	Buy	16,481 +1,761	+12%	+$29	﹤0.01%	14099
2023 Q2	$294	Sell	14,720 -2,419	-14%	-$44	﹤0.01%	14158
2023 Q1	$278	Buy	+17,139	New	+$430	﹤0.01%	14532

Other funds holding REVBW

Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return

PVI

Pine Valley Investments Marlton, New Jersey $2.18B AUM 26.57% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

WAM

Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

SIA

Soltis Investment Advisors St. George, Utah $1.59B AUM 23.87% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

QWM

Quaker Wealth Management Moorestown, New Jersey $320M AUM 13.7% 1-Year Est. Return

Citadel Advisors's REVBW Position: Q1 2026 in Review

Citadel Advisors increased its Revelation Biosciences Warrant (REVBW) stake by 0.94% in Q1 2026, buying an estimated $3 and bringing the position to 32,400 shares worth $285. The position accounts for ﹤0.01% of the portfolio, ranked #12856.

Citadel Advisors first reported a position in REVBW in Q1 2023 and has held it in 13 quarters since. The position peaked at $1.23K in Q1 2024. 11 funds tracked by Wall St. Rank hold REVBW as of Q1 2026.

Citadel Advisors held 32,400 shares of Revelation Biosciences Warrant worth $285 as of Q1 2026.
Citadel Advisors bought 302 Revelation Biosciences Warrant shares in Q1 2026, an estimated $3.
Revelation Biosciences Warrant made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #12856 holding.
Citadel Advisors first reported a position in Revelation Biosciences Warrant in Q1 2023 and has held it in 13 quarters since.
Citadel Advisors's Revelation Biosciences Warrant position peaked at $1.23K in Q1 2024.
11 funds tracked by Wall St. Rank held Revelation Biosciences Warrant as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.